Prognostic inflammatory–immune score-based risk stratification optimizes adjuvant therapy for non-gastric gastrointestinal stromal tumors: a multicenter study

1

The study developed a Prognostic Inflammatory–Immune Score (PIIS) to improve risk stratification for non-gastric gastrointestinal stromal tumors (GISTs).
2

A multicenter cohort of 471 patients was analyzed, integrating hematological variables with clinicopathological factors to create a nomogram.
3

The PIIS included the platelet-to-albumin ratio, platelet-to-lymphocyte ratio, derived neutrophil-to-lymphocyte ratio, and lactate dehydrogenase-to-albumin ratio.
4

The integrated model showed superior discrimination in predicting recurrence-free survival compared to conventional mNIH and AFIP systems.
5

Adjuvant therapy beyond 3 years improved recurrence-free survival in medium- and high-risk subgroups but not in low-risk patients.

Frontiers In Immunology

by Zhiming Cai, Zhengnan Xu, Huimei Lin, Huibin Liu, Zihan Lin, Jinhu Chen, Shichai Hong, Weibin Song, Xinyu Chen, Yanchang Xu, Zhenrong Yang, Yongjian Zhou
June 2, 2026

1